Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Neddylation, RIPK3 Degradation, and Viral Inflammation
2026-10-14
A primary Immunity study links an orthopoxvirus protein to SCF-dependent RIPK3 degradation, necroptosis suppression, and altered inflammation. MLN4924 HCl salt provides a conceptual pharmacological entry point for studying NEDD8-activating enzyme and cullin-RING ligase biology, but the supplied study does not establish that this compound was used or that NAE inhibition reproduces viral protein loss.
Erastin and Ferroptosis: Evidence and Boundaries
2026-10-13
Erastin is a research tool for studying ferroptosis and oxidative cell death, but the supplied renal-injury study supports a context-specific mechanistic interpretation rather than broad claims about cancer selectivity, clinical treatment, or supplier-specific performance.
What iTBS Findings in SCA3 Mice Show
2026-10-12
A recent mouse study reports that intermittent theta-burst stimulation improved motor coordination and altered cerebellar markers linked to ataxin-3 aggregation, neuroinflammation, and autophagy. The findings are mechanistically suggestive but remain preliminary: the work was conducted in a transgenic mouse model, used a small sample, and did not establish long-term disease modification or relevance to people with SCA3.
Erastin, Ferroptosis, and ROS: Evidence Boundaries
2026-10-12
Erastin is commonly described as a ferroptosis inducer, but the supplied evidence does not connect it directly to the reported carrier-platin study. Liu et al. describe a distinct, preclinical platinum-based approach to rapid ROS-associated cancer-cell death, while important questions remain about mechanism, selectivity, reproducibility, and clinical relevance.
Erastin Beyond the Benchmark: Ferroptosis to Translation
2026-10-11
Erastin is more than a ferroptosis inducer: it is a mechanistic lens for studying redox vulnerability, tumor heterogeneity, and the immune consequences of oxidative cell death. This analysis connects preclinical evidence with translational questions without overstating clinical readiness.
Erastin and Ferroptosis: Evidence, Scope, and Limits
2026-10-10
A source-grounded overview of Erastin as a ferroptosis inducer, explaining ferroptosis principles, the strength of available evidence, interpretation of HCC findings, and the boundaries of conclusions from cell and database studies.
Bafilomycin C1 in Lysosomal and Cardiac Research
2026-10-09
Bafilomycin C1 is commonly described as a vacuolar H+-ATPases inhibitor for studying lysosomal acidification, autophagy, and intracellular trafficking. This overview separates supplier information from peer-reviewed evidence and examines how lysosomal perturbation could be interpreted in high-content cardiotoxicity research without treating indirect findings as proof of compound-specific effects.
RNA Pol II Inhibition and Active Cell Death Signaling
2026-10-09
Harper et al. show that RNA polymerase II inhibition can trigger apoptosis through active signaling rather than passive loss of transcription-dependent gene products. The study identifies loss of hypophosphorylated RNA Pol IIA and defines a Pol II degradation-dependent apoptotic response, providing a framework for interpreting transcription-targeting therapies in cancer research.
From Surface Labeling to Spatial Proteome Maps
2026-10-08
Spatial proteomics is moving beyond isolated markers toward cell-type-resolved molecular maps of intact tissue. This thought-leadership article examines how membrane-restricted tyramide chemistry can support that transition, what the 2025 PSPro study demonstrates, and where Biotin-XX Tyramide Reagent fits—without confusing conceptual relevance with direct validation.
DDIT4 Links Microplastics to Kidney Organoid Injury
2026-10-08
A 2025 study used human pluripotent stem cell-derived kidney organoids to examine how 1 μm polystyrene microplastics affect nephron development. The findings connect organoid injury with DDIT4-associated mTOR suppression, autophagy, and apoptosis, while also highlighting the limits of translating an organoid model into environmental or clinical risk estimates.
Sodium Picosulfate and the Gut–Brain Axis
2026-10-07
A translational perspective on Sodium Picosulfate as a defined gastrointestinal perturbation for studying motility, electrolyte handling, microbiota, and neuroinflammation—while distinguishing supplier evidence from findings reported in a rat hepatic encephalopathy imaging study.
CFDA SE Cell Tracer Kit Overview
2026-10-07
The CFDA SE Cell Tracer Kit (SKU K1023) is an APExBIO product containing carboxyfluorescein diacetate succinimidyl ester for supplier-described fluorescent cell labeling and conceptual applications in cell lineage tracing and cell proliferation studies. No matched paper evidence or independent performance data were provided.
LmPLK1 in Locust Gut Growth and Molting
2026-10-06
The reference study characterizes LmPLK1 as a regulator connecting cell-cycle activity in the locust midgut with tissue maintenance, molting, and 20-hydroxyecdysone signaling. Its RNA-interference findings support LmPLK1 as a biologically important pest-control target, although the evidence remains species-specific and requires further validation beyond the reported study system.
Direct Mouse Genotyping Kit Plus: From Genotype to Evidence
2026-10-06
The Direct Mouse Genotyping Kit Plus can simplify genotype confirmation in mouse disease models through direct lysate PCR and a PCR master mix with dye reagents. This article examines its scientific role in protecting model validity, using recent SCA3/MJD neuromodulation research to distinguish genotyping evidence from mechanistic conclusions.
CCCP in Mitochondrial Research: Evidence and Limits
2026-10-05
CCCP, or carbonyl cyanide m-chlorophenyl hydrazine, is best understood as a mechanistic perturbation tool for studying proton motive force and oxidative phosphorylation rather than as a disease-specific reagent. This overview compares the mechanistic rationale for CCCP with findings from a 2025 study using urine-derived stem-cell mitochondrial morphology and deep learning to investigate Alzheimer’s disease, while distinguishing reported evidence from proposed applications and highlighting limits on clinical interpretation.